Sign Up Today and Learn More About Maze Therapeutics Stock
Invest in or calculate the value of your shares in Maze Therapeutics or other pre-IPO companies through EquityZen's platform.
Maze Therapeutics Stock (MAZT)
Maze Therapeutics is a biotechnology company that develops precision medicines for renal, cardiovascular, and metabolic diseases.
About Maze Therapeutics Stock
Founded
2018
Headquarters
South San Francisco, CA, US
Industries
Software, Artificial Intelligence, Data and Analytics
Maze Therapeutics Press Mentions
Stay in the know about the latest news on Maze Therapeutics
Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
biospace • May 13, 2026
Nexviazyme (Sanofi: avalglucosidase alfa-ngpt) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F
globenewswire • May 07, 2026
Maze Therapeutics Announces $150 Million Registered Offering
biospace • Apr 24, 2026
San Francisco Pharma Co.'s HORIZON Phase 2 Data Validates APOL1 Path to Pivotal Trial Research Report
streetwisereports • Apr 09, 2026
Wave Plummets 50% on Obesity Data
genengnews • Mar 31, 2026
Maze Therapeutics Management
Leadership team at Maze Therapeutics
Board Member
Charles Homcy
Board Member
Vineeta Agarwala
Join now and verify your accreditation status to gain access to:
- Maze Therapeutics Current Valuation
- Maze Therapeutics Stock Price
- Maze Therapeutics Management
- Available deals in Maze Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Maze Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Maze Therapeutics Revenue and Financials
- Maze Therapeutics Highlights
- Maze Therapeutics Business Model
- Maze Therapeutics Risk Factors
- Maze Therapeutics Research Report from SACRA Research
Trading Maze Therapeutics Stock
How to invest in Maze Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Maze Therapeutics through EquityZen funds. These investments are made available by existing Maze Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process for buying Pre-IPO Shares.
How to sell Maze Therapeutics stock?
Shareholders can sell their Maze Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 450K accredited investors interested in buying private company stock. Learn more about the Shareholder liquidity process.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. See more information on Express Deals and pre-IPO exit information.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 53K private placements completed across 500+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
